Prognosis
Pfizer Covid Vaccine First to Seek Emergency U.S. Approval
- Shot developed with company’s German partner BioNTech
- Vaccine found to be 95% effective with no major safety issues
This article is for subscribers only.
Pfizer Inc. filed with U.S. regulators for an emergency-use authorization for its Covid-19 vaccine, seeking clearance for an experimental shot that’s expected to play an important role in an immunization effort to halt the virus.
The vaccine, developed by the U.S. drugmaker with its German partner BioNTech SE, is the first to seek authorization from the Food and Drug Administration. An emergency clearance would allow Americans to access the vaccine before it’s granted full approval. It is likely to be the first to be made available on a limited basis to health workers and older Americans.